基本信息 产品详情 公司简介 推荐产品
网站主页 化工产品目录 有机原料 杂环化合物 CYC-065 化合物 CYC065
  • 化合物 CYC065|TQ0053|TargetMol

化合物 CYC065|TQ0053|TargetMol

Fadraciclib
1070790-89-4
696 1mg 起订
1690 5mg 起订
2380 10mg 起订
上海 更新日期:2024-12-12

TargetMol中国(陶术生物)

VIP3年
联系人:邵小姐
手机:4008200310 拨打
邮箱:marketing@tsbiochem.com

产品详情:

中文名称:
化合物 CYC065
英文名称:
Fadraciclib
CAS号:
1070790-89-4
品牌:
TargetMol
产地:
美国
保存条件:
Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
纯度规格:
99.75%
产品类别:
抑制剂
货号:
TQ0053

Product Introduction

Bioactivity

名称Fadraciclib
描述Fadraciclib (CYC065) is an orally available, second-generation ATP-competitive inhibitor of CDK2/CDK9 kinases (IC50s: 5/26 nM).
细胞实验Briefly, tumour cells are plated in six-well plates and treated with a titration of CYC065 concentrations (i.e., ranging from 100 to 500?nM). After 72?h, cells are harvested, washed and stained with propidium iodide (PI; 5?μg/mL) for flow cytometric counts. The percentage of viable cells is then normalized considering the vehicle-treated cells as 100% viable. Half-maximal inhibitory concentration values are determined using GraphPad Prism5 version 6. For drug combination studies, USC-ARK-1 and USC-ARK-2 cell lines are incubated with the combination of Taselisib and CYC065 at multiple paired concentrations including the IC50, the IC50/2 and the IC50*2 of each cell line to the corresponding drug (i.e., 10?nM of Taselisib and 198?nM of CYC065 for USC-ARK-1 and 50?nM of Taselisib and 62.5?nM of CYC065 for USC-ARK-2). Synergism is assessed by the combination index (CI). CI values <1 define a synergistic activity of the combination treatment. The CI values are calculated using the CompuSyn software [1].
动物实验Briefly, 5-7-week-old SCID mice are injected into the subcutaneous region with USC cells. A minimum of five animals per group are used. Treatments are administrated by oral gavage starting 1 week after tumor implantation when the size of the tumor is 0.125-0.150?cm3. Uterine serous carcinoma-ARK-2-derived xenografts are divided into two groups: one group of animal receive the vehicle, whereas the experimental group receives CYC065 (22.5?mg/kg daily for 3 weeks). Uterine serous carcinoma-ARK-1-derived xenografts are instead divided into four groups: one group receive the vehicle (0.5% methylcellulose-0.2% Tween-80), one group receive CYC065 (22.5?mg/kg daily for 3 weeks), one group receive Taselisib (10 mg/kg daily, 5 days per week per 3 weeks) and the last group receive the combination of CYC065 and Taselisib. The size of the tumor at the initiation of treatment is 0.125-0.150?cm3. Mouse weight and tumor size is recorded two times a week for the entire experimental period. Tumor volume is calculated.
体外活性CYC065通过阻碍细胞在细胞周期G1阶段的活动,并特异性抑制在环形蛋白E1 (CCNE1) 过表达的子宫浆液性癌症(USCs)中的细胞生长。与低CCNE1表达的细胞系相比,高CCNE1 mRNA及蛋白水平的USC细胞系对CYC065的治疗表现出更高的敏感性(IC50: 平均±标准差=124.1±57.8nM 对CCNE1过表达的USC细胞系 vs 415±117.5nM 对CCNE1低表达者;P=0.0003)。重要的是,低浓度的CYC065(即,100nM)仅在CCNE1过表达的USC细胞系中引起细胞周期G1阶段的停滞[1]。
体内活性USC-ARK-2衍生的异种移植物每日使用CYC065 (22.5 mg/kg)治疗共3周。肿瘤大小与小鼠体重每周记录两次。CYC065的日常给药显著减缓了与对照组相比的肿瘤生长(治疗第9天起,P=0.012)。整个治疗期间未报告有显著的体重减轻[1]。
存储条件Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
溶解度DMSO : 100 mg/mL (251.56 mM)
关键字Inhibitor | inhibit | Fadraciclib | Cyclin dependent kinase | CYC-065 | CYC 065 | CDK
相关产品Sodium Oxamate | Ribociclib | Palbociclib monohydrochloride | Abemaciclib methanesulfonate | CASIN | Olomoucine | Palbociclib | GW 441756 | Dinaciclib | Ro-3306 | GSK 3 Inhibitor IX | Abemaciclib
相关库抑制剂库 | 经典已知活性库 | 抗癌活性化合物库 | 已知活性化合物库 | 抗胰腺癌化合物库 | ReFRAME 相关化合物库 | 激酶抑制剂库 | 抗衰老化合物库 | 血液病分子库 | 药物功能重定位化合物库 | 抗癌临床化合物库 | 抗癌药物库
CYC065|TargetMol

公司简介

TargetMol Chemicals Inc. 总部位于马萨诸塞州波士顿,致力于为全球生化领域科学家的研究提供专业的产品和服务。TargetMol?品牌的客户群分布于40多个国家和地区,已发展成为全球知名的化合物库和小分子化合物研究供应商。 TargetMol?可提供160多种满足不同需求的化合物库,以及多种类型的生化试剂产品,包括12000多种抑制剂、16000多种天然产物和各类多肽、抗体、生命科学试剂盒等,此外,我们还建设有CADD(计算机辅助药物设计)研究中心、药理实验室、药化合成平台三大技术中心,全方位满足客户的定制需求。 凭借我们优质的产品和服务、快速高效的全球供应链和专业的技术支持,我们将有效帮助您缩短研发周期,取得更成功的结果。

成立日期 (12年)
注册资本 566.265100万人民币
员工人数 100-500人
年营业额 ¥ 1亿以上
经营模式 贸易,工厂,试剂,定制,服务
主营行业 天然产物,生化试剂,分子生物学,分子砌块,生物技术服务

化合物 CYC065相关厂家报价

内容声明
拨打电话 立即询价